SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : TATRADER GIZZARD STUDY--Stocks 12.00 or Less..... -- Ignore unavailable to you. Want to Upgrade?

To: TATRADER who wrote (56566)10/30/2006 10:20:46 AM
From: Smiling Bob  Read Replies (1) | Respond to of 59879
 
I bought some Jan 5 calls on RNVS, now 3.62. Seems a good risk/reward with little capital tied up .30 ask



To: TATRADER who wrote (56566)10/30/2006 10:33:35 AM
From: lexi2004  Read Replies (1) | Respond to of 59879
 
FDA extends review of Genta leukemia drug
at Reuters (Mon 8:26am)

GNTA pulled back from premarket .86 or so and hit .80...lots of shares going through. Currently .81. Might be getting ready to move.

Lexi


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News